Cooper Companies, Inc. (The) (NYSE:COO) Director Gary S. Petersmeyer sold 3,977 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $244.94, for a total value of $974,126.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Gary S. Petersmeyer also recently made the following trade(s):

  • On Thursday, June 29th, Gary S. Petersmeyer sold 100 shares of Cooper Companies, Inc. (The) stock. The shares were sold at an average price of $239.78, for a total value of $23,978.00.

Shares of Cooper Companies, Inc. (NYSE COO) traded up 0.16% during midday trading on Thursday, hitting $247.00. The stock had a trading volume of 359,754 shares. Cooper Companies, Inc. has a 52-week low of $158.73 and a 52-week high of $256.39. The firm has a market cap of $12.07 billion, a price-to-earnings ratio of 37.03 and a beta of 0.59. The firm’s 50 day moving average price is $245.27 and its 200 day moving average price is $224.26.

Cooper Companies, Inc. (The) (NYSE:COO) last released its quarterly earnings data on Thursday, August 31st. The medical device company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.58 by $0.06. Cooper Companies, Inc. (The) had a return on equity of 16.00% and a net margin of 16.45%. The firm had revenue of $556.00 million for the quarter, compared to analysts’ expectations of $552.32 million. During the same period in the prior year, the firm posted $2.30 earnings per share. The firm’s quarterly revenue was up 8.0% on a year-over-year basis. On average, equities research analysts expect that Cooper Companies, Inc. will post $9.72 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Cooper Companies, Inc. (The) (COO) Director Sells $974,126.38 in Stock” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/14/cooper-companies-inc-the-coo-director-sells-974126-38-in-stock.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in COO. Capstone Asset Management Co. acquired a new position in Cooper Companies, Inc. (The) in the first quarter valued at approximately $269,000. Profund Advisors LLC lifted its holdings in Cooper Companies, Inc. (The) by 9.1% in the first quarter. Profund Advisors LLC now owns 2,059 shares of the medical device company’s stock valued at $412,000 after acquiring an additional 171 shares during the last quarter. ProShare Advisors LLC lifted its holdings in Cooper Companies, Inc. (The) by 1.5% in the first quarter. ProShare Advisors LLC now owns 4,896 shares of the medical device company’s stock valued at $979,000 after acquiring an additional 73 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Cooper Companies, Inc. (The) by 33.7% in the first quarter. Wells Fargo & Company MN now owns 152,303 shares of the medical device company’s stock valued at $30,443,000 after acquiring an additional 38,379 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI acquired a new position in Cooper Companies, Inc. (The) in the first quarter valued at approximately $237,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

A number of equities research analysts have issued reports on COO shares. Robert W. Baird restated a “buy” rating and set a $273.00 price objective (up from $267.00) on shares of Cooper Companies, Inc. (The) in a research report on Tuesday. Zacks Investment Research upgraded Cooper Companies, Inc. (The) from a “hold” rating to a “buy” rating and set a $277.00 price objective on the stock in a research report on Tuesday, August 29th. J P Morgan Chase & Co restated a “neutral” rating and set a $206.00 price objective (up from $200.00) on shares of Cooper Companies, Inc. (The) in a research report on Monday, June 5th. Jefferies Group LLC set a $250.00 price objective on Cooper Companies, Inc. (The) and gave the company a “buy” rating in a research report on Thursday, August 17th. Finally, Oppenheimer Holdings, Inc. restated a “hold” rating and set a $250.00 price objective on shares of Cooper Companies, Inc. (The) in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Cooper Companies, Inc. (The) presently has an average rating of “Buy” and an average price target of $257.60.

Cooper Companies, Inc. (The) Company Profile

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Insider Buying and Selling by Quarter for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related companies with MarketBeat.com's FREE daily email newsletter.